MicroPort Orthopedics Receives Long-Term ODEP Rating for its Advance® Medial-Pivot Knee System

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, has received a “15A” rating for its Advance® Medial-Pivot knee system from the Orthopaedic Data Evaluation Panel (ODEP).

Fifteen (15) years is the longest benchmark that ODEP assigns ratings for knee implants, providing further evidence of the long clinical heritage of the Advance® Medial-Pivot knee system. ODEP was established in 2002, and provides an independent review of clinical data to assign ratings and share information about the success of arthroplasty implants.

MicroPort Orthopedics’ medial-pivot knee systems stand on more than 20 years of clinically demonstrated history with a complete portfolio of medial-pivot design knees. The Advance® Medial-Pivot knee system was built on the latest kinematic evidence of the natural stability and motion of the knee.1 Its innovative design is carried on by MicroPort’s latest medial-pivot knee, the Evolution® Medial-Pivot knee system, which also aims to restore function by replicating natural motion and stability, and to address some of the common problems seen with traditional designs, such as anterior knee pain and quadriceps avoidance.

The design and successful clinical heritage of MicroPort Orthopedics’ medial-pivot knee systems sets them apart from the competition. A legacy of 98.8 percent survivorship over 17 years and 95 percent patient satisfaction supports its ability to restore stability and normal kinematics. This helps surgeons achieve favorable, reproducible, and long-lasting outcomes for their patients. 2-5
 
“It’s our goal at MicroPort to develop innovative products and procedures that help providers improve patient outcomes, facilitate fast recovery and a return to normal life activities,” says Irina Timmerman, the Vice President of Regulatory and Clinical Affairs at MicroPort Orthopedics. “This rating from ODEP further validates MicroPort’s medial-pivot knee systems’ ability to produce consistent and long-lasting results.”

REFERENCES

1. George A. Macheras et al. “A long term clinical outcome of the Medial Pivot Knee Arthroplasty System.” The Knee Journal, January 29, 2017.

2. Patient satisfaction at 2 months following total knee replacement using a second generation medial-pivot system: follow-up of 250 consecutive cases. Van Overschelde P et al. Ann Transl Med 2016

3. Pritchett JW. Patients prefer a bicruciate-retaining or the medial pivot total knee prosthesis. J Arthroplasty. 2011;26:224–228.

4. Miyazaki Y et al. Analysis of the Kinematics of Total Knee Prostheses With a Medial Pivot Design. J Arthroplasty. 2011; 26(7):1038-1044.

5. Lamontagne M et al.. Muscle Activity in Total Knee Arthroplasty Patients While Ascending and Descending a Ramp. Orthopaedic Proceedings, 2019. 101-B(SUPP_5): p. 59-59.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”